Werewolf debuts with $56M to develop tumor-activated biologics

Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of cytokines and immuno-stimulatory antibodies by masking their activity until they reach the tumor microenvironment.

MPM Capital and Longwood Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...